About MaRS Innovation MaRS Innovation is the commercialization agent for Ontario's exceptional discovery pipeline from 15 leading academic institutions, including Baycrest
Centre for Geriatric
Care,
Centre for Addiction and Mental
Health, Holland Bloorview Kids Rehabilitation Hospital, The Hospital for Sick Children (SickKids), MaRS Discovery District, Mount Sinai Hospital, Ontario Institute for Cancer Research, St. Michael's Hospital, Ryerson University, Sunnybrook
Health Sciences
Centre, Thunder Bay Regional Research Institute, University
Health Network, University of Toronto, Women's College Hospital and
York University.
From the Department of Medicine, Division of Hematology, Brigham and Women's Hospital (S.J., A.J.S., M.M.) and Harvard Medical School (B.L.E.), the Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital (E.S.) and Harvard Medical School (G.K.S., P.L.), the Department of Pathology (S.J.) and the Center for Genomic Medicine (P.N., S.K.), Massachusetts General Hospital, the Department of Medicine, Division of Cardiology, and Cardiovascular Research Center (P.N., S.K.), and the Department of Medicine (A.G.B.), Massachusetts General Hospital and Harvard Medical School, and the Departments of Medical Oncology (C.J.G.) and Biostatistics and Computational Biology (D.N.), Dana - Farber Cancer Institute, Boston, and the Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge (P.N., A.G.B., N.G., S.G., S.K.)- all in Massachusetts; the Department of Cardiology, University Hospital, Parma, Italy (D.A.); the Department of Medicine, Division of Cardiology, Mt. Sinai School of Medicine, New
York (U.B., R.M., V.F.); Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid (V.F.); Medical Research Council - British Heart Foundation Cardiovascular Epidemiology Unit and National Institute for
Health Research Blood and Transplant Research Unit in Donor
Health and Genomics, Department of Public
Health and Primary
Care, and the British Heart Foundation, Cambridge
Centre of Excellence, Department of Medicine, University of Cambridge, Cambridge (J.D.), and the Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton (J.D.)- both in the United Kingdom; the Center for Non-Communicable Diseases, Karachi, Pakistan (P.F., D.S.); the Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia (D.S.); and the Department of Clinical Sciences Malmö, Lund University, Lund, Sweden (O.M.).